Research Insight
Phase III Trial of Regorafenib in Patients with Unresectable...
Bayer announced that a Phase III trial evaluating its oncology compound regorafenib (Stivarga®) for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met...
Research Insight
Novartis drug Afinitor® reduces seizures patients with tuberous sclerosis...
Novartis announced results from a Phase III study showing Afinitor®* (everolimus), when used as an adjunctive therapy, significantly reduced treatment-resistant seizures associated with tuberous sclerosis...
Research Insight
The use of Surgical Patch TachoSil (human thrombin/human fibrogen)...
Takeda Pharmaceutical Company Limited announced that the European Commission has granted an expanded indication for surgical patch TachoSil (human thrombin/human fibrogen) for use in adults...
Research Insight
Bristol-Myers Squibb’s Opdivo Receives Breakthrough Therapy Designation from US...
Designation based on results of Phase 3 study, CheckMate -141, in which Opdivo met its primary endpoint of overall survival, versus three standard of care...
Research Insight
AbbVie, CytomX to co-develop for Probody Drug Conjugates
AbbVie and CytomX Therapeutics, Inc announced that they have entered into a collaboration to co-develop and co-commercialize Probodyâ„¢ Drug Conjugates against CD71, also known...
Research Insight
OFIRMEV (Acetaminophen) Injection Health Economic Data Presented and Specially...
Mallinckrodt plc a leading global specialty biopharmaceutical company announced the results from a retrospective analysis of health economic data on the use of OFIRMEV (acetaminophen)...
Research Insight
Teva announced new data from the Phase III placebo-controlled...
Teva Pharmaceutical Industries Ltd., announced new data from the Phase III placebo-controlled and randomized First Time Use of SD-809 in HuntingtonDisease (First-HD) study evaluating the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.